Wells Fargo upgraded GoodRx from Equal Weight to Overweight and set a new price target of $10.00 from $7.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2024 | $10.00 | Outperform → Strong Buy | Raymond James |
| 5/23/2024 | $8.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 5/16/2024 | $10.00 | Mkt Perform → Outperform | Raymond James |
| 4/10/2024 | $9.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 3/25/2024 | $7.50 → $10.00 | Equal Weight → Overweight | Wells Fargo |
| 3/1/2024 | $7.00 → $10.00 | Neutral → Overweight | JP Morgan |
| 2/26/2024 | $8.00 | Outperform | Leerink Partners |
| 1/2/2024 | $8.00 → $4.50 | Buy → Underperform | BofA Securities |
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
Former Chief Financial Officer of The Honest Company brings over 25 years of experience across retail and consumer brands GoodRx (NASDAQ:GDRX), a leading resource for healthcare savings and information, today announced the election of Kelly J. Kennedy to its Board of Directors. Kennedy will serve as a member of the Board's audit committee and fill the seat left vacant by Jacqueline Kosecoff earlier this year. With over 25 years of experience serving in senior financial roles for leading retail and consumer brands, Kennedy brings extensive experience overseeing risk assessment management and financial reporting at large public companies. Currently, Kennedy serves as Chief Financial Offic
Amino Health, the leading digital healthcare navigation company, today announced the appointment of John Asalone to the role of Chief Executive Officer. He succeeds David Vivero, the company's visionary founder and CEO, who steps into a new role as Chairman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231213064342/en/John Asalone, Amino Health CEO (Photo: Business Wire) Asalone, who joined Amino this past August as COO, is a seasoned executive with 20 years of experience scaling software and marketplace companies. Previously the SVP of Growth Verticals at GoodRx (NASDAQ:GDRX), Asalone specializes in bringing consumer-grade ex
Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv
3 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00
RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously
Raymond James upgraded GoodRx from Mkt Perform to Outperform and set a new price target of $10.00
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $195.3 million Net income of $4.0 million; Net income margin of 2.0% Adjusted Net Income1 of $31.9 million; Adjusted Net Income Margin1 of 16.4% Adjusted EBITDA1 of $65.0 million; Adjusted EBITDA Margin1 of 33.3% Net cash provided by operating activities of $86.9 million Exited the quarter with over 7 million consumers of prescription-related offerings2 "In a world where there is increasing attention on medicin
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://inve
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $200.6 million Net income of $6.7 million; Net income margin of 3.3% Adjusted Net Income1 of $32.4 million; Adjusted Net Income Margin1 of 16.1% Adjusted EBITDA1 of $65.4 million; Adjusted EBITDA Margin1 of 32.6% Net cash provided by operating activities of $9.7 million Exited the quarter with over 7 million consumers of prescription-related offerings2 "We're proud of the progress we're making against
New Partnership with GoodRx to Lower Costs for Uninsured and Underinsured Patients Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., providing patients with discounts on select Harrow products. This initiative reflects Harrow's ongoing commitment to making essential, sight-saving medications accessible and affordable. A core component of Harrow's
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $195.3 million Net income of $4.0 million; Net income margin of 2.0% Adjusted Net Income1 of $31.9 million; Adjusted Net Income Margin1 of 16.4% Adjusted EBITDA1 of $65.0 million; Adjusted EBITDA Margin1 of 33.3% Net cash provided by operating activities of $86.9 million Exited the quarter with over 7 million consumers of prescription-related offerings2 "In a world where there is increasing attention on medicin
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced that executives from the Company will participate in a fireside chat at each of the following investor conferences: UBS 2024 Global Healthcare Conference in Rancho Palos Verdes, CA, on Tuesday, November 12, 2024 at 2 p.m. Eastern Time (11 a.m. Pacific Time) Citi 2024 Global Healthcare Conference in Miami, FL, on Thursday, December 5, 2024 at 8:45 a.m. Eastern Time (5:45 a.m. Pacific Time) A live webcast of each of the foregoing events will be available on the Company's Investor Relations website, https://investors.goodrx.com/. Following each conferenc
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
Boehringer Ingelheim and GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., announced today a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer's biosimilar to Humira® (adalimumab), at a low cash price available exclusively on GoodRx. This program is a significant step in addressing access and affordability in one of the largest therapeutic categories with a high cost burden for patients. Adalimumab-adbm is an FDA-approved interchangeable* biosimilar to Humira®. The citrate-free, injectable medication is used to treat or reduce the signs and symptoms of certain autoimmune conditions, such as rheumatoid arthritis, Crohn's diseas
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Monday. Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply during Monday's session amid a rise Bitcoin. Bitcoin prices rose past the key $63,000 level on Monday. MicroStrategy shares jumped 11.5% to $1,556.89 during the session. Here are some other big stocks recording gains in today’s session. Trump Media & Technology Group Corp. (NASDAQ:DJT) shares jumped 32.8% to $41.03 following the attempted assassination of Donald Trump. The company's CEO Devin Nunes issued the following statement in response to the attempted assassination of President Donald J. Trump, “I offer my deepest sympath
Reveals Consumers Paid $21B Out-of-Pocket in 2024, Averaging $16.26 Per Prescription